Analysis of risk factors for skin disorders caused by anti‐epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.

What is known and Objective: Cancer drug treatment is often discontinued because of skin disorder aggravation. However, information on risk factors for skin disorders caused by anti‐epidermal growth factor receptor (EGFR) antibody drugs is limited. The aim of this study was to analyse the factors associated with skin disorders caused by anti‐EGFR antibody drugs and establish a method to minimize such aggravations. Methods: We retrospectively examined 67 colorectal cancer patients treated with anti‐EGFR antibody drugs for the first time. Results and discussion: A higher proportion of males than females experienced drug withdrawal, dose reduction or treatment discontinuation. The multiple logistic regression analysis revealed body weight as a risk factor affecting drug withdrawal, dose reduction or treatment discontinuation because of an acneiform rash. An examination of methods to avoid the aggravation of skin disorders revealed the acneiform rash grade in patients who received prophylactic minocycline was significantly lower than that in patients who did not receive prophylactic minocycline. Furthermore, among patients with grade 1 acneiform rash at the initiation of minocycline, the proportion of those who withdrew, required dose reduction or discontinued treatment was lower than that among patients with grade 2 acneiform rash. What is new and Conclusion: High body weight was identified as a novel factor for skin disorder aggravation caused by anti‐EGFR antibody drugs. The aggravation of skin disorders during cancer treatment with anti‐EGFR antibody drugs can potentially be avoided by carefully observing the onset of acneiform rash in affected patients with high body weight and using minocycline prophylactically or as an early‐stage intervention. [ABSTRACT FROM AUTHOR]